TKI Therapy in EGFR Gene Mutation Lung Cancers and Interpreting Clinical Trials | Lung Cancer Nursing UK

TKI Therapy in EGFR Gene Mutation Lung Cancers and Interpreting Clinical Trials

Thursday 27th February, 18:00 - 19:00

For our second webinar of the year we are joined by Dr Alastair Greystoke, who is an Honorary Medical Oncologist at Newcastle’s Northern Centre for Cancer Care specialising in lung cancer, frailty in cancer, personalised medicine and drug development. He is also a Lecturer in Medical Oncology at Newcastle University.

Learning outcomes for this webinar:

  • Present and emerging therapies in metastatic disease
  • Roles of Osimertinib in earlier stage disease
  • “Should I scan my patient's head”?
  • “Should I be doing liquid biopsy? When and how?”

All healthcare professionals are welcome to join this webinar and to participate in the Q&A session that will follow the presentation.

This webinar programme has been instigated by Lung Cancer Nursing UK. Sponsorship has been received by AstraZeneca UK Ltd to support the costs of this webinar series.  AstraZeneca has had no input into the development of topics, selection of speakers or the content of the webinars

If you wish to learn more about AstraZeneca’s lung cancer brands please reach out to your local AstraZeneca Oncology Account Manager.

Speakers

  • Alastair Greystoke

    Newcastle upon Tyne Hospitals NHS Trust
    Dr Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust. He is one of 4 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle, and has a special interest in the development of new anti-cancer drugs for patients with lung cancer. He is a member of Lung CSG, leads systemic therapy research for NSCLC in the North-East, with a portfolio of Phase I-IV studies and is the sub-specialty lead for lung cancer for the North-East England and North Cumbria NIHR CRN. In addition he is the Clinical Lead for Cancer for the Yorkshire, Hull and North East England Genomic Laboratory Hub, the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in lung cancer), and leads the Pharmacodynamic Biomarker team at Newcastle University Cancer.